Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008; P. R. China; Institute of Clinical Pharmacology, Central South University; Hunan Key Laboratory of Pharmacogenetics, Changsha 410078; P. R. China; Department of critical care medicine, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.
Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008; P. R. China; Institute of Clinical Pharmacology, Central South University; Hunan Key Laboratory of Pharmacogenetics, Changsha 410078; P. R. China.
Metabolism. 2014 Aug;63(8):1012-21. doi: 10.1016/j.metabol.2014.05.006. Epub 2014 May 15.
Current whole genome-wide association study has identified the association of JAZF1 with type 2 diabetes; its close relation with glucose and lipid metabolism has also been revealed. However, to date, JAZF1 remains a relatively new gene with unknown function.
MATERIALS/METHODS: We constructed JAZF1 overexpression vector and synthesized JAZF1 siRNA, then transfected them into 3T3-L1 adipocytes, investigated the relationship between the regulations of JAZF1, visfatin, and other adipokines, researched the specific function of JAZF1 in glucose and lipid metabolism.
This study found that the expression of JAZF1 was gradually but significantly upregulated during the induced differentiation of 3T3-L1 preadipocytes, and that the trend of its expression was consistent with that of visfatin. Further studies indicated that JAZF1 promoted the expressions of visfatin, PPARα, and PPARβ/δ in adipocytes but simultaneously inhibited the expressions of TAK1 and PPARγ. Luciferase reporter assay revealed that JAZF1 activated the transcription of visfatin, but ChIP assay results indicated that JAZF1 did not directly bind to visfatin PPRE. Our results also showed that the JAZF1 overexpression-increased visfatin expression was abolished by the addition of PPARα antagonist GW 6471 and PPARβ/δ antagonist GSK 3787 respectively. And these results were further confirmed by the experiment with PPARα and PPARβ/δ siRNAs. Meanwhile, we also found that JAZF1 inhibited the lipid accumulation during the differentiation of 3T3-L1 into mature adipocyte.
Our results indicate that JAZF1 might firstly upregulated the expression of PPARα and PPARβ/δ, which in turn activated the transcription of visfatin. JAZF1 plays an important role in lipid metabolism and may thus provide a potential tool for the treatment of obesity and lipid metabolism disorders among other diseases.
目前全基因组关联研究已经发现 JAZF1 与 2 型糖尿病有关;其与葡萄糖和脂质代谢的密切关系也已被揭示。然而,迄今为止,JAZF1 仍然是一个相对较新的功能未知的基因。
材料/方法:我们构建了 JAZF1 过表达载体并合成了 JAZF1 siRNA,然后将其转染到 3T3-L1 脂肪细胞中,研究了 JAZF1 调节、内脂素和其他脂肪细胞因子之间的关系,研究了 JAZF1 在葡萄糖和脂质代谢中的具体功能。
本研究发现,在 3T3-L1 前脂肪细胞的诱导分化过程中,JAZF1 的表达逐渐但显著上调,其表达趋势与内脂素一致。进一步的研究表明,JAZF1 促进脂肪细胞中内脂素、PPARα 和 PPARβ/δ 的表达,但同时抑制 TAK1 和 PPARγ 的表达。荧光素酶报告基因检测显示,JAZF1 激活了内脂素的转录,但 ChIP 检测结果表明,JAZF1 并未直接结合到内脂素 PPRE 上。我们的结果还表明,JAZF1 过表达增加的内脂素表达被 PPARα 拮抗剂 GW 6471 和 PPARβ/δ 拮抗剂 GSK 3787 分别抑制。这些结果进一步通过 PPARα 和 PPARβ/δ siRNA 的实验得到证实。同时,我们还发现 JAZF1 抑制了 3T3-L1 向成熟脂肪细胞分化过程中的脂质积累。
我们的结果表明,JAZF1 可能首先上调 PPARα 和 PPARβ/δ 的表达,进而激活内脂素的转录。JAZF1 在脂质代谢中起重要作用,因此可能为肥胖和脂质代谢紊乱等疾病的治疗提供一种潜在的工具。